Dan Rasmussen & D.A. Wallach on Biotech’s Surge, China, IPOs, US Valuations & Japan | #617 - The Meb Faber Show - Better Investing Recap
Podcast: The Meb Faber Show - Better Investing
Published: 2026-02-09
Duration: 1 hr 16 min
Summary
Dan Rasmussen and D.A. Wallach explore the unique dynamics of the biotech sector, highlighting its significant return distribution, the ineffectiveness of traditional investment models, and the potential for substantial gains despite a high percentage of money-losing companies.
What Happened
In this episode, Meb Faber welcomes back Dan Rasmussen and D.A. Wallach to discuss the recent surge in biotech stocks, which have risen by 50% since their last appearance. The conversation dives deep into the intricacies of the biotech sector, emphasizing how traditional investment models often fail to apply. Dan shares insights from a paper he authored, which scrutinizes the factors that drive asset prices in biotech. He explains that most biotech companies are unprofitable, with around 70% losing money, making it a sector where typical valuation methods like price-to-earnings ratios do not hold up.
Rasmussen reveals that biotech is characterized by a unique distribution of returns, where a small percentage of companies drive the majority of gains. The discussion points out that while many biotech firms struggle financially, those that do succeed can yield enormous returns, akin to lottery tickets. The duo explores how to redefine value in this sector, suggesting that investors should focus on the relationship between market cap and spending rather than traditional metrics. This nuanced understanding is crucial for investors looking to navigate the complexities of biotech investing, especially given its high level of internal dispersion and correlation with broader market trends.
Key Insights
- Biotech stocks have surged by 50% since the last discussion with Rasmussen and Wallach.
- 70% of biotech companies are unprofitable, making traditional valuation methods ineffective.
- A small percentage of biotech firms drive the majority of returns, highlighting a lottery-like investment scenario.
- Investors should redefine value in biotech by comparing market cap to company spending rather than using standard metrics.
Key Questions Answered
What factors drive asset prices in biotech?
Traditional investment factors like value, quality, and momentum do not apply in biotech, as these companies are often unprofitable. Dan explains that the best way to approach value in biotech is by examining spending relative to market cap, rather than relying on conventional metrics, which do not capture the reality of this sector.
Why do most biotech companies lose money?
Dan highlights that around 70% of biotech firms are money losers, which is a significant statistic for the industry. These companies often focus on research and development without generating revenue, leading to a high percentage of firms that struggle financially.
How can investors navigate the biotech sector effectively?
Investors can navigate biotech by understanding its unique characteristics, such as high dispersion and the fact that traditional factors do not work. By focusing on how much these companies are spending relative to their market cap, investors can identify potential opportunities in a sector that is otherwise inscrutable.
What is the significance of the recent surge in biotech stocks?
The recent 50% increase in biotech stocks since the last episode indicates a potential inflection point in the sector. This surge reflects investor optimism and a renewed interest in biotech, which may suggest that the market is starting to recognize the potential value in companies that had previously been overlooked.
What insights did Dan Rasmussen gain from his research on biotech?
Rasmussen's research revealed that traditional equity models fail to account for the unique factors affecting biotech. He found that while many companies are losing money, the few that succeed can provide massive returns, supporting the notion that investing in biotech can be akin to playing the lottery, but with the potential for substantial rewards.